刘花;陈延绅;尤慧柠;冯燕;程锴;李敏;寇建蓉;封卫毅;

• 1:西安交通大学第一附属医院药学部

摘要(Abstract)：

长春瑞滨作为一种细胞周期特异性抗肿瘤药物,临床疗效好,加之口服方便,越来越多地被应用于肿瘤的节拍化疗。目前长春瑞滨用于节拍化疗的治疗方案依赖于经验用药,且有关长春瑞滨节拍化疗作用机制的研究资料相对较少并缺乏系统性的总结,因此有必要对长春瑞滨用于节拍化疗的药动学特点和作用机制进行总结,以期为临床肿瘤患者给药方案的制定提供参考。研究表明,长春瑞滨用于节拍化疗的抗肿瘤机制涉及抑制肿瘤血管新生、促进细胞的凋亡与自噬、刺激抗肿瘤免疫以及诱导炎症反应等多种因素,是一种多靶点的抗肿瘤治疗方案。

关键词(KeyWords)： 长春瑞滨;节拍化疗;药动学;作用机制

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金面上项目（编号81972814）

作者(Authors): 刘花;陈延绅;尤慧柠;冯燕;程锴;李敏;寇建蓉;封卫毅;

DOI: 10.19577/j.1007-4406.2022.01.016

参考文献(References)：

• [1]CAMERINI A,MORABITO A,MONTANINO A,et al.Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy:results of the randomized phaseⅡTempo Lung trial[J].ESMO Open,2021,6(2):100051.
• [2]PLATANIA M,PASINI F,PORCU L,et al.Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy:the MA.NI.LA.multicenter,randomized,controlled,phaseⅡtrial[J].Lung Cancer,2019,132:17.
• [3]ESTEVINHO F,GOMES R,HASMUCRAI D,et al.Metronomic oral vinorelbine in a real-world population of advanced non-small cell lung cancer patients[J].Pulmonology,2020:2531.
• [4]XU K,LIU T,ZHANG J,et al.The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with nonsmall cell lung cancer:a meta-analysis[J].Int J Clin Oncol,2020,25(9):1624.
• [5]LIU C T,HSIEH M C,SU Y L,et al.Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer:a retrospective,observational study[J].J Cancer,2021,12(17):5355.
• [6]LIANG W H,GUAN W J,CHEN R C,et al.Cancer patients in SARS-CoV-2 infection:a nationwide analysis in China[J].Lancet Oncol,2020,21(3):335.
• [7]CAPASSO A.Vinorelbine in cancer therapy[J].Curr Drug Targets,2012,13(8):1065.
• [8]YAMAUCHI K,YANG M,HAYASHI K,et al.Induction of cancer metastasis by cyclophosphamide pretreatment of host mice:an opposite effect of chemotherapy[J].Cancer Res,2008,68(2):516.
• [9]GRALLA R J,GATZEMEIER U,GEBBIA V,e t a l.O r a l vinorelbine in the treatment of non-small cell lung cancer:rationale and implications for patient management[J].Drugs,2007,67(10):1403.
• [10]PéTAIN A,ZHONG D F,CHEN X Y,et al.Effect of ethnicity on vinorelbine pharmacokinetics:a population pharmacokinetics analysis[J].Cancer Chemother Pharmacol,2019,84(2):373.
• [11]MARTY M,FUMOLEAU P,ADENIS A,et al.Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors[J].Ann Oncol,2001,12(11):1643.
• [12]BRIASOULIS E,PAPPAS P,PUOZZO C,et al.Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer[J].Clin Cancer Res,2009,15(20):6454.
• [13]BRIASOULIS E,ARAVANTINOS G,KOUVATSEAS G,et al.Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer:a Hellenic cooperative oncology group clinical translational study[J].BMC Cancer,2013,13:263.
• [14]KERBEL R S,KAMEN B A.The anti-angiogenic basis of metronomic chemotherapy[J].Nat Rev Cancer,2004,4(6):423.
• [15]DAENEN L G,SHAKED Y,MAN S,et al.Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models[J].Mol Cancer Ther,2009,8(10):2872.
• [16]FAN F J,SCHIMMING A,JAEGER D,et al.Targeting the tumor microenvironment:focus on angiogenesis[J].J Oncol,2012,2012:281261.
• [17]LI T,KANG G,WANG T,et al.Tumor angiogenesis and antiangiogenic gene therapy for cancer[J].Oncol Lett,2018,16(1):687.
• [18]GUO D Q,MURDOCH C E,LIU T H,et al.Therapeutic angiogenesis of Chinese herbal medicines in ischemic heart disease:a review[J].Front Pharmacol,2018,9:428.
• [19]MELINCOVICI C S,BO狢A A B,猆狹AN S,et al.Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis[J].Rom J Morphol Embryol,2018,59(2):455.
• [20]QIN R S,ZHANG Z H,ZHU N P,et al.Enhanced antitumor and antiangiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma[J].BMC Cancer,2018,18(1):967.
• [21]CAMERINI A,PUCCETTI C,DONATI S,et al.Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer:results of a phase II trial (MOVE trial)[J].BMC Cancer,2015,15:359.
• [22]BURSTEIN H J,CHEN Y H,PARKER L M,et al.VEGF as a marker for outcome among advanced breast cancer patients receiving antiVEGF therapy with bevacizumab and vinorelbine chemotherapy[J].Clin Cancer Res,2008,14(23):7871.
• [23]KAREVA I,WAXMAN D J,LAKKA KLEMENT G.Metronomic chemotherapy:an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance[J].Cancer Lett,2015,358(2):100.
• [24]ZHANG Y Y,KONG L Q,ZHU X D,et al.CD31 regulates metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma via the ITGB1-FAK-Akt signaling pathway[J].Cancer Lett,2018,429:29.
• [25]BIZIOTA E,BRIASOULIS E,MAVROEIDIS L,et al.Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells[J].Anticancer Drugs,2016,27(3):216.
• [26]MANCUSO P,COLLEONI M,CALLERI A,et al.Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy[J].Blood,2006,108(2):452.
• [27]PFEFFER C,SINGH A.Apoptosis:a target for anticancer therapy[J].Int J Mol Sci,2018,19(2):448.
• [28]KACZANOWSKI S.Apoptosis:its origin,history,maintenance and the medical implications for cancer and aging[J].Phys Biol,2016,13(3):031001.
• [29]LEVY J M M,TOWERS C G,THORBURN A.Targeting autophagy in cancer[J].Nat Rev Cancer,2017,17(9):528.
• [30]LI X,HE S,MA B.Autophagy and autophagy-related proteins in cancer[J].Mol Cancer,2020,19(1):12.
• [31]CERRITO M G,DE GIORGI M,PELIZZONI D,et al.Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triplenegative breast cancer cells.Results from the proof-of-concept VICTOR-0 study[J].Oncotarget,2018,9(44):27448.
• [32]付校,潘永成,王建军,等.自噬在长春瑞滨诱导的肺癌细胞A549死亡中的作用[J].中国肺癌杂志,2008,11(3):345.
• [33]KOUMARIANOU A,CHRISTODOULOU M I,PATAPIS P,et al.The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients[J].Exp Hematol Oncol,2014,3(1):3.
• [34]LUTSIAK M E,SEMNANI R T,De PASCALIS R,et al.Inhibition of CD4(+)25+T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide[J].Blood,2005,105(7):2862.
• [35]ORECCHIONI S,TALARICO G,LABANCA V,et al.Vinorelbine,cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma[J].Br JCancer,2018,118(10):1329.
• [36]SHEVCHENKO I,KARAKHANOVA S,SOLTEK S,et al.Lowdose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer[J].Int J Cancer,2013,133(1):98.
• [37]SANTOS P M,BUTTERFIELD L H.Dendritic cell-based cancer vaccines[J].J Immunol,2018,200(2):443.
• [38]SABADO R L,BALAN S,BHARDWAJ N.Dendritic cell-based immunotherapy[J].Cell Res,2017,27(1):74.
• [39]TANAKA H,MATSUSHIMA H,MIZUMOTO N,et al.Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells[J].Cancer Res,2009,69(17):6978.
• [40]SHURIN G V,TOURKOVA I L,KANENO R,et al.Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism[J].J Immunol,2009,183(1):137.
• [41]DAI J,EL GAZZAR M,LI G Y,et al.Myeloid-derived suppressor cells:paradoxical roles in infection and immunity[J].J Innate Immun,2015,7(2):116.
• [42]NAGARAJ S,GABRILOVICH D I.Tumor escape mechanism governed by myeloid-derived suppressor cells[J].Cancer Res,2008,68(8):2561.
• [43]GALLUZZI L,BUQUéA,KEPP O,et al.Immunological effects of conventional chemotherapy and targeted anticancer agents[J].Cancer Cell,2015,28(6):690.
• [44]ALTINOZ M A,OZPINAR A,ALTURFA N E E,e t a l.Vinorelbine's anti-tumor actions may depend on the mitotic apoptosis,autophagy and inflammation:hypotheses with implications for chemo-immunotherapy of advanced cancers and pediatric gliomas[J].J Chemother,2018,30(4):203.
• [45]TSAI K L,HUANG P H,KAO C L,et al.Aspirin attenuates vinorelbine-induced endothelial inflammation via modulating SIRT1/AMPK axis[J].Biochem Pharmacol,2014,88(2):189.
• [46]BALKWILL F,CHARLES K A,MANTOVANI A.Smoldering and polarized inflammation in the initiation and promotion of malignant disease[J].Cancer Cell,2005,7(3):211.
• [47]ELHARRAR X,BARBOLOSI D,CICCOLINI J,et al.A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma:rationale and study protocol[J].BMC Cancer,2016,16:278.
• [48]COHEN S,SCHWARTZ M,DOTTINO P,et al.Use of a multidrug regimen gemcitabine,5-fluorouracil,irinotecan,cisplatin,bevacizumab,docetaxel,and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian,fallopian tube and primary peritoneal cancer[J].J Ovarian Res,2019,12(1):36.
• [49]DE LUCA A,GRASSII M,MAIELLO M R,et al.Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?[J].Anticancer Res,2004,24(5A):2985.
• [50]SOLIMAN E,HENDERSON K L,DANELL A S,et al.Arachidonoylethanolamide activates endoplasmic Reticulum stress-apoptosis in tumorigenic keratinocytes:Role of cyclooxygenase-2 and novel J-series prostamides[J].Mol Carcinog,2016,55(2):117.
• [51]ELMACI I,BILIR A,OZPINAR A,et al.Gemcitabine,vinorelbine and cyclooxygenase inhibitors in the treatment of glioblastoma.Ultrastructural analyses in C6 glioma in vitro[J].Tissue Cell,2019,59:18.
• [52]WU T,DAI Y.Tumor microenvironment and therapeutic response[J].Cancer Lett,2017,387:61.